174 related articles for article (PubMed ID: 23915193)
41. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
42. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
Ely SA; Knowles DM
Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
[TBL] [Abstract][Full Text] [Related]
43. TIMP Loss Activates Metalloproteinase-TNFα-DKK1 Axis To Compromise Wnt Signaling and Bone Mass.
Chen Y; Aiken A; Saw S; Weiss A; Fang H; Khokha R
J Bone Miner Res; 2019 Jan; 34(1):182-194. PubMed ID: 30216540
[TBL] [Abstract][Full Text] [Related]
44. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass DA; Bialek P; Ahn JD; Starbuck M; Patel MS; Clevers H; Taketo MM; Long F; McMahon AP; Lang RA; Karsenty G
Dev Cell; 2005 May; 8(5):751-64. PubMed ID: 15866165
[TBL] [Abstract][Full Text] [Related]
45. Roles of TNF-α, GSK-3β and RANKL in the occurrence and development of diabetic osteoporosis.
Qi J; Hu KS; Yang HL
Int J Clin Exp Pathol; 2015; 8(10):11995-2004. PubMed ID: 26722385
[TBL] [Abstract][Full Text] [Related]
46. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.
Li J; Sarosi I; Cattley RC; Pretorius J; Asuncion F; Grisanti M; Morony S; Adamu S; Geng Z; Qiu W; Kostenuik P; Lacey DL; Simonet WS; Bolon B; Qian X; Shalhoub V; Ominsky MS; Zhu Ke H; Li X; Richards WG
Bone; 2006 Oct; 39(4):754-66. PubMed ID: 16730481
[TBL] [Abstract][Full Text] [Related]
47. Mesenchymal stem cell abnormalities in patients with multiple myeloma.
Garderet L; Mazurier C; Chapel A; Ernou I; Boutin L; Holy X; Gorin NC; Lopez M; Doucet C; Lataillade JJ
Leuk Lymphoma; 2007 Oct; 48(10):2032-41. PubMed ID: 17917971
[TBL] [Abstract][Full Text] [Related]
48. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
49. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
50. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
51. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
[TBL] [Abstract][Full Text] [Related]
52. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
53. Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling.
Wang D; Weng Y; Guo S; Zhang Y; Zhou T; Zhang M; Wang L; Ma J
Int J Mol Med; 2018 Feb; 41(2):729-738. PubMed ID: 29207140
[TBL] [Abstract][Full Text] [Related]
54. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
55. Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells.
Granchi D; Baglìo SR; Amato I; Giunti A; Baldini N
Int J Cancer; 2008 Oct; 123(7):1526-35. PubMed ID: 18623132
[TBL] [Abstract][Full Text] [Related]
56. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients.
Andersson MK; Lundberg P; Ohlin A; Perry MJ; Lie A; Stark A; Lerner UH
Arthritis Res Ther; 2007; 9(1):R18. PubMed ID: 17316439
[TBL] [Abstract][Full Text] [Related]
57. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
Feng Y; Zhang Y; Wei X; Zhang Q
Cancer Biomark; 2019; 24(2):195-201. PubMed ID: 30614800
[TBL] [Abstract][Full Text] [Related]
58. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.
Giuliani N; Rizzoli V
Leuk Lymphoma; 2007 Dec; 48(12):2323-9. PubMed ID: 18067006
[TBL] [Abstract][Full Text] [Related]
59. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
60. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
Clines GA; Mohammad KS; Bao Y; Stephens OW; Suva LJ; Shaughnessy JD; Fox JW; Chirgwin JM; Guise TA
Mol Endocrinol; 2007 Feb; 21(2):486-98. PubMed ID: 17068196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
